HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
KF 22678
structure in first source
Also Known As:
KF-22678; KF22678
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrans: 130
KF 22678: 1
Related Diseases
1.
Neoplasms (Cancer)
10/01/1999 - "
KF22678 exhibited low cross-resistance against various drug-resistant cell lines of MDR1 or MRP overexpressing human tumors, and, in addition, exhibited more potent antitumor activity in vivo than ADM against A2780/ADM and KB/MRP xenograft.
"
10/01/1999 - "
In addition, the antitumor activity of KF22678 against BSO-pretreated human lung carcinoma PC-9 tumor was significantly decreased.
"
10/01/1999 - "
KF22678, a novel thioester derivative of leinamycin with the 1-oxo-1,2-dithiolane-3-one moiety, was examined for anti-tumor activity, toxicity in mice and activation mechanism.
"
2.
Carcinoma (Carcinomatosis)
10/01/1999 - "
KF22678 showed a broad antitumor spectrum against human carcinoma xenografts (lung, colon, ovary and prostate).
"
10/01/1999 - "
In addition, the antitumor activity of KF22678 against BSO-pretreated human lung carcinoma PC-9 tumor was significantly decreased.
"
10/01/1999 - "
DL-Buthionine sulfoximine (BSO) pretreatment significantly reduced intracellular glutathione (GSH) level in human lung carcinoma A549 cells, leading to decrease in the cytotoxicity of KF22678, whereas the cytotoxicity of melphalan was augmented by BSO pretreatment.
"
Related Drugs and Biologics
1.
Buthionine Sulfoximine
2.
Melphalan (Alkeran)
3.
Glutathione (Reduced Glutathione)
4.
leinamycin (DC 107)